# The Efficacy and Safety of Benmelstobart for GC/EGC

> **NCT06603974** · NA · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **PROCEDURE:** surgery
- **DRUG:** Benmelstobart
- **DRUG:** tegafur
- **DRUG:** oxaliplatin
- **DRUG:** albumin paclitaxel

## Key facts

- **NCT ID:** NCT06603974
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-16
- **Primary completion:** 2026-07-26
- **Final completion:** 2026-12-26
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603974, "The Efficacy and Safety of Benmelstobart for GC/EGC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06603974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*